1051375-10-0

Basic information

• Product Name: Cabotegravir (GSK744, GSK1265744)
• Synonyms: GSK1265744;GSK744;(3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide;Cabotegravir (GSK744, GSK1265744);Cabotegravir Free Acid;Cabotegravir;Cyclic pyranopterin;SK744, GSK1265744
• CAS NO: 1051375-10-0
• Molecular Formula: C19H17F2N3O5
• Molecular Weight: 405.3521864
• Product Categories: Inhibitors
• Mol File: 1051375-10-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 664.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.57±0.1 g/cm3(Predicted)
• Solubility: insoluble in H2O; insoluble in EtOH; ≥19.35 mg/mL in DMSO with gentle warming
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: Cabotegravir (GSK744, GSK1265744)(CAS DataBase Reference)
• NIST Chemistry Reference: Cabotegravir (GSK744, GSK1265744)(1051375-10-0)
• EPA Substance Registry System: Cabotegravir (GSK744, GSK1265744)(1051375-10-0)

Safety Data

• Hazardous Substances Data: 1051375-10-0(Hazardous Substances Data)

Usage

Biological Activity

Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, inhibiting HIV-1 integrase-catalyzed strand transfer with IC50 of 3 nM. Phase 2.

Mechanism of action

Caboggravir is a potent inhibitor of HIV integrase, which prevents the HIV virus from infecting human cells, while rilpivirine prevents the virus from replicating itself.

Upstream product

• 1616340-68-1 methyl 5-((2,4-difluorobenzyl)carbamoyl)-1-(2,2-dirnethoxyethyl)-3-methoxy-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 72235-52-0 2,4-Difluoro-benzylamine 
• 1335210-23-5 1-[2,2-bis(methyloxy)ethyl]-5-(methyloxy)-6-[(methyloxy)carbonyl]-4-oxo-1,4-dihydro-3-pyridinecarboxylic acid 
• 1335210-26-8 methyl 2-(((2,2-dimethoxyethyl)amino)methylene)-4-methoxy-3-oxobutanoate 
• 1335210-25-7 (4R,12aS)-N-(2,4-difluorobenzyl)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1’,2’:4,5]pyrazino[2,1-b]oxazine-9-carboxamide 

Downstream Products

• 1206168-05-9 {[(3S,11aR)-8-({[(2,4-difluorophenyl)methyl]amino}carbonyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-yl]oxy}methyl methyl carbonate 

Relevant articles and documents

Process for Preparation of Intermediates Used for the Synthesis of HIV Integrase Inhibitor

Provided herein is a process for the intermediates used for preparation of HIV Integrase Inhibitor such as Bictegravir, Dolutegravir, Cabotegravir or their pharmaceutically acceptable salts.

NOVEL POLYMOPRPHS AND SALTS OF POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES

The present invention provides novel polymorphs of (3S,11aR)-N-[(2,4-difluorophenyl) methyl]-6- hydroxy-3-methyl-5, 7-dioxo-2, 3,5,7, 11, 11a-hexahydro[1, 3]oxazolo[3, 2-a]pyrido[1, 2-d]pyrazine-8-carboxamide including sodium and potassium salts and pharm

(3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10

The compounds are intermediates in the preparation of therapeutic agents useful in the treatment of viral infections, particularly HIV infection. The compounds are (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenylmethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10.